Global Eyewear Giant EssilorLuxottica Acquires AI-Powered Ophthalmic Health Tech Firm RetinAI
Essilor
Lens Product Design and Manufacturer
Ikerian
Developer of Medical Software Solutions
The company stated that this acquisition strengthens the group's development in the medical technology field, injecting it with advanced software based on machine learning and computer vision, further...Expand itsEye Health Medical Service Ecosystem.
RetinAI was founded in 2017 and is headquartered in Switzerland. The company focuses on developing advanced tools for collecting, processing, and evaluating large-scale retinal image and biomarker datasets.
Its flagship platform, RetinAI Discovery, has received FDA 510(k) clearance and CE certification. The platform applies artificial intelligence models to support the diagnosis and monitoring of disease progression, including age-related macular degeneration (AMD), glaucoma, and diabetic retinopathy, enabling more accurate and timely decisions in eye disease management.
At the same time, RetinAI collaborates with pharmaceutical giantsBoehringer IngelheimCollaborate with research institutions to leverage proprietary real-world evidence for accelerating clinical research and drug development.
The acquirer, Essilor, originated in France, formed by the merger of two historic eyewear companies — Essel (founded in 1849) and Silor (founded in 1931).
Essilor has pioneered multiple breakthroughs in the history of optical eyewear, including being the first to use resin lenses as a substitute for glass lenses, as well as introducingAspherical DesignAndProgressive technology, etc.
In recent years,EssilorActively transforming from a traditional eyewear manufacturer toIntelligent Vision Technology CompanyTransformation.Its core strategy is to focus on smart glasses, deeply integrating AI technology with its strengths in optics, design, and global distribution.。
Including andTech GiantMetaDeep cooperation, launching the popular Ray-Ban Meta smart glasses series,AndTencent HealthCollaboratively develop AI eye health assistant, expand digital services, etc.
Regarding this acquisition, the chairman and CEO of Essilor stated: "By leveraging its artificial intelligence analysis technology, we can transform clinical data into insights, enabling faster and more accurate diagnoses as well as more effective disease monitoring. We are ushering in a new era of healthcare that will bring transformative changes for patients around the world."
—END—
